휴온스글로벌

084110· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩22,050-0.68%

2026-09-18

Financials

Valuation Metrics

휴온스글로벌's Market Cap is ₩2791B. At end of 2025 it was ₩6482B. Ranked #697 of 2,421 in KR market (top 29%), #296 of 1,640 on KOSDAQ (top 18%), #76 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 33%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	279.15B KRW	KR#697/2,421 Sec#76/231
Revenue	846.78B KRW	KR#446/2,421 Sec#19/231
Net Income	59.47B KRW	KR#362/2,421 Sec#25/231
Total Assets	1.54T KRW	KR#366/2,421 Sec#16/231
Net Assets	1.09T KRW	KR#277/2,421 Sec#14/231
Employees	121	KR#1,497/2,421 Sec#119/231
Value
P/E	4.69x	KR#308/2,421 Sec#10/231
P/B	0.26x	KR#228/2,421 Sec#7/231
PEG	0.02x	KR#185/2,421 Sec#7/231
P/S	0.33x	KR#640/2,421 Sec#19/231
EV/EBITDA	7.36x	KR#409/2,421 Sec#15/231
FCF Yield	17.33%	KR#374/2,421 Sec#9/231
Profitability
ROE	5.46%	KR#1,045/2,421 Sec#71/231
ROA	3.86%	KR#901/2,421 Sec#73/231
Op. Margin	8.08%	KR#654/2,421 Sec#53/231
Revenue Growth	4.07%	KR#1,259/2,421 Sec#129/231
Earnings Growth	221.67%	KR#228/2,421 Sec#13/231
Financial Health
Debt Ratio	41.41%	KR#823/2,421 Sec#95/231
Total Debt	414.25B KRW	KR#346/2,421 Sec#13/231
FCF	48.38B KRW	KR#307/2,421 Sec#17/231
Cash	190.24B KRW	KR#281/2,421 Sec#11/231
Current Ratio	1.65x	KR#1,079/2,421 Sec#120/231
Net Debt/EBITDA	3.27x	KR#921/2,421 Sec#69/231
Dividend
Div. Yield	4.03%	KR#412/2,421 Sec#15/231
Div. Growth	67.62%	KR#178/2,421 Sec#5/231
Performance
1Y Return	-50.06%	KR#2,059/2,421 Sec#188/231
1M Return	-4.96%	KR#1,788/2,421 Sec#143/231
From 52W High	-71.25%	KR#2,219/2,421 Sec#192/231
1Y MDD	-72.64%	KR#2,099/2,421 Sec#184/231
Trading
Volume	16,753 shares	KR#1,664/2,421 Sec#164/231
Trading Value	370.2M KRW	KR#1,054/2,421 Sec#106/231
Foreign Own.	7.30%	KR#613/2,421 Sec#52/231
Per Share
EPS	4,697 KRW	KR#230/2,421 Sec#13/231
BPS	85,967 KRW	KR#164/2,421 Sec#9/231

Company Info

CEO Song Soo-young, Yoon Sung-Tae (Independent representation)

Employees 121

Founded 1987

HQ 경기도 성남시, KR

Website www.huonsglobal.com

Established as Gwangmyeong Pharmaceutical Industries in 1965, the company transitioned into a holding company in 2016. In 2021, it physically spun off its bio business, now operating as a pure holding company. As a healthcare group with 13 affiliates, including Huons and Humedix, it boasts a diverse business portfolio spanning pharmaceutical manufacturing, fillers, arthritis treatments, and medical devices. The company generates revenue from trademark usage, management consulting, dividends, and rental income, providing management guidance through subsidiary stake acquisition and ownership. Huons Global was established in 1987 and is headquartered in Seongnam-si, Gyeonggi-do.